Avalo Therapeutics (NASDAQ:AVTX) Insider Mittie Doyle Sells 1,450 Shares of Stock

Avalo Therapeutics, Inc. (NASDAQ:AVTX) insider Mittie Doyle sold 1,450 shares of Avalo Therapeutics stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $18.00, for a total transaction of $26,100.00. Following the transaction, the insider directly owned 51,776 shares in the company, valued at $931,968. The trade was a 2.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mittie Doyle also recently made the following trade(s):

• On Monday, April 6th, Mittie Doyle sold 3,970 shares of Avalo Therapeutics stock. The shares were sold at an average price of $18.01, for a total transaction of $71,499.70.
• On Wednesday, April 1st, Mittie Doyle sold 679 shares of Avalo Therapeutics stock. The stock was sold at an average price of $16.00, for a total transaction of $10,864.00.

Avalo Therapeutics Price Performance

Shares of NASDAQ AVTX traded down $0.16 during midday trading on Thursday, reaching $18.00. 1,689,258 shares of the stock were exchanged, compared to its average volume of 1,168,646. The business has a 50-day simple moving average of $15.75 and a two-hundred day simple moving average of $16.09. The company has a market capitalization of $946.26 million, a price-to-earnings ratio of -3.30 and a beta of 0.83. Avalo Therapeutics, Inc. has a 12 month low of $4.53 and a 12 month high of $24.27.

Avalo Therapeutics (NASDAQ:AVTX) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.98) EPS for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.02. Equities research analysts expect that Avalo Therapeutics, Inc. will post -2.58 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on AVTX shares. Weiss Ratings upgraded Avalo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 15th. Citizens Jmp dropped their target price on shares of Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating on the stock in a report on Thursday, May 14th. Wolfe Research began coverage on shares of Avalo Therapeutics in a research note on Thursday, April 9th. They issued an “outperform” rating and a $48.00 price target on the stock. Piper Sandler reiterated an “overweight” rating and issued a $60.00 price target (up from $48.00) on shares of Avalo Therapeutics in a report on Monday, May 11th. Finally, Wall Street Zen raised shares of Avalo Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Sunday, March 29th. Twelve analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Avalo Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $46.67.

Institutional Trading of Avalo Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Caligan Partners LP acquired a new position in Avalo Therapeutics during the third quarter worth $10,592,000. Balyasny Asset Management L.P. bought a new stake in Avalo Therapeutics during the 3rd quarter worth about $10,390,000. Vanguard Group Inc. boosted its stake in shares of Avalo Therapeutics by 314.9% during the 3rd quarter. Vanguard Group Inc. now owns 692,637 shares of the company’s stock worth $8,803,000 after buying an additional 525,696 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Avalo Therapeutics by 380.2% during the 4th quarter. Millennium Management LLC now owns 659,979 shares of the company’s stock worth $11,985,000 after buying an additional 522,548 shares during the last quarter. Finally, Seven Fleet Capital Management LP grew its holdings in shares of Avalo Therapeutics by 806.0% in the 1st quarter. Seven Fleet Capital Management LP now owns 573,883 shares of the company’s stock valued at $8,568,000 after acquiring an additional 510,540 shares in the last quarter. 87.06% of the stock is currently owned by institutional investors and hedge funds.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.